SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively trending due to breaking news of a Department of Justice criminal probe into Fed Chair Jerome Powell, which the community widely perceives as unprecedented political pressure on the central bank. This development is sparking intense debate among investors about the Federal Reserve's independence and its potential impact on future monetary policy, raising concerns about market stability and the dollar's credibility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following its CES 2026 showcase, where it unveiled significant advancements in agentic voice and visual AI, including new partnerships with TomTom for multi-agent navigation and Richtech Robotics for automated food systems. The community is actively discussing these innovative applications in automotive and robotics, fueled by ongoing speculation about a potential short squeeze due to the stock's high short interest. Investors are keenly watching SOUN's position in the expanding AI market, highlighting its unique white-label solutions as a competitive advantage.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is currently trending due to heightened competitive pressures in the weight-loss market, specifically Amazon Pharmacy's offering of Novo Nordisk's oral GLP-1 at competitive prices, a product HIMS currently lacks. This news, compounded by a recent analyst downgrade, has driven significant bearish sentiment and a notable price correction. However, a segment of the community views the dip as an oversold opportunity, emphasizing HIMS' long-term strategy in personalized healthcare, proprietary compounding labs, and international expansion beyond just weight-loss treatments.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum driven by its announcement of a record total contract value exceeding a billion and a major new collaboration in genomic testing with Northwestern Medicine. The community is actively discussing the company's AI-driven growth, strategic partnerships, and Cathie Wood's recent share acquisitions, leading to speculation about further gains in the precision medicine sector.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing extreme volatility following news of a new manufacturing partnership and a $10 million private placement, sparking intense debate between its operational progress and immediate dilution concerns. Community discussion centers on the potential for a massive short squeeze, with many comparing it to previous low-float runners, while others caution about dilution from the recent offering and the stock's significant price fluctuations.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics ($ATRA) is experiencing a significant downturn and intense community discussion after receiving a Complete Response Letter (CRL) from the FDA for its EBVALLO BLA, citing issues solely related to a third-party manufacturing facility rather than the drug's clinical efficacy or safety. While many express frustration over the unexpected delay and potential for dilution, a substantial portion of the community views this as an "overreaction" and a strategic buying opportunity, given the drug's existing approval in Europe and the high unmet medical need. Attention is now focused on the timeline for resolving manufacturing concerns, potential resubmission, and the company's exploration of strategic alternatives, including a possible acquisition by its partner, Pierre Fabre.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is highly discussed following new AI partnerships with Google, which integrate Gemini for enhanced shopping experiences and expand drone delivery services. The community is actively buzzing about this strategic pivot, viewing WMT increasingly as a tech-enabled retailer ahead of its anticipated Nasdaq-100 inclusion. This narrative emphasizes Walmart's innovation and evolving market position, sparking conversations about its "growth tech stock" valuation.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending, primarily driven by community discussions around the potential for its LitVM and BTC_OS developments to enhance utility through programmable money and cross-chain interoperability. This is further amplified by speculation on tightening on-exchange liquidity and growing institutional interest, though a significant portion of the community remains skeptical, highlighting historical underperformance and questioning its long-term demand.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending following strong preliminary financial results that anticipate beating revenue guidance and an expanded partnership with Bio-Rad Laboratories to develop high-complexity cancer diagnostic assays. This positive news, coupled with significant insider buying, has fueled a surge in interest and bullish sentiment. However, community discussions are polarized, with some celebrating growth and strategic advancements, while others remain cautious due to a recent reverse stock split and ongoing concerns about cash burn.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as the community anticipates potential strategic updates from management at an upcoming healthcare conference, intensifying discussions around its perceived undervaluation and calls for new partnerships or a buyout. Investors are keenly focused on the company's protein-based vaccine platform and advanced adjuvant technology, while high short interest adds to the debate over its near-term trajectory amidst a dynamic biotech market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

ARTC
ArthroCare Corporation

Feed

News

Sentiment

Fundamentals

Info

Latest ARTC News

ARTCArthroCare Corporation